Hence, the expression of TNFR1 and of RIPK1/RIPK3/MLKL proteins by tumor cells, in conjunction with the production of TNFα in the tumor microenvironment, could represent novel biomarkers for cisplatin sensitivity in apoptosis-resistant tumors. This evidence concerns the gene RIPK3 and neoplasm.